CN101848725B - 组合物 - Google Patents

组合物 Download PDF

Info

Publication number
CN101848725B
CN101848725B CN2008801138365A CN200880113836A CN101848725B CN 101848725 B CN101848725 B CN 101848725B CN 2008801138365 A CN2008801138365 A CN 2008801138365A CN 200880113836 A CN200880113836 A CN 200880113836A CN 101848725 B CN101848725 B CN 101848725B
Authority
CN
China
Prior art keywords
mbp
peptide
hla
peptides
apitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801138365A
Other languages
English (en)
Chinese (zh)
Other versions
CN101848725A (zh
Inventor
戴维·赖思
希瑟·斯特里特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baimingxinkang Biotechnology Zhejiang Co ltd
Original Assignee
Apitope Technology Bristol Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721430A external-priority patent/GB0721430D0/en
Priority claimed from GB0800962A external-priority patent/GB0800962D0/en
Application filed by Apitope Technology Bristol Ltd filed Critical Apitope Technology Bristol Ltd
Publication of CN101848725A publication Critical patent/CN101848725A/zh
Application granted granted Critical
Publication of CN101848725B publication Critical patent/CN101848725B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)
CN2008801138365A 2007-10-31 2008-10-30 组合物 Active CN101848725B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0721430.7 2007-10-31
GB0721430A GB0721430D0 (en) 2007-10-31 2007-10-31 Composition
GB0800962A GB0800962D0 (en) 2008-01-18 2008-01-18 Conposition
GB0800962.3 2008-01-18
PCT/GB2008/003673 WO2009056833A2 (en) 2007-10-31 2008-10-30 Composition

Publications (2)

Publication Number Publication Date
CN101848725A CN101848725A (zh) 2010-09-29
CN101848725B true CN101848725B (zh) 2013-05-22

Family

ID=40591554

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801138365A Active CN101848725B (zh) 2007-10-31 2008-10-30 组合物

Country Status (23)

Country Link
US (3) US8623827B2 (enExample)
EP (1) EP2211892B1 (enExample)
JP (1) JP5361895B2 (enExample)
KR (1) KR101570383B1 (enExample)
CN (1) CN101848725B (enExample)
AT (1) ATE518546T1 (enExample)
AU (1) AU2008320657B2 (enExample)
BR (1) BRPI0818302B1 (enExample)
CA (1) CA2703170C (enExample)
CY (1) CY1112620T1 (enExample)
DK (1) DK2211892T3 (enExample)
EA (1) EA017999B1 (enExample)
EC (1) ECSP10010211A (enExample)
HR (1) HRP20110724T1 (enExample)
IL (1) IL204662A (enExample)
MX (1) MX2010004698A (enExample)
MY (1) MY158800A (enExample)
NZ (1) NZ583924A (enExample)
PL (1) PL2211892T3 (enExample)
PT (1) PT2211892E (enExample)
SI (1) SI2211892T1 (enExample)
WO (1) WO2009056833A2 (enExample)
ZA (1) ZA201001748B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1311542T1 (sl) 2000-08-21 2009-02-28 Apitope Technology Bristol Ltd Tolerogenski peptidi
US8623827B2 (en) 2007-10-31 2014-01-07 Apitope Technology (Bristol) Limited Myelin basic protein peptide composition
WO2011046462A1 (en) * 2009-10-12 2011-04-21 Angport Limited Composition for treatment of multiple sclerosis
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201603582D0 (en) * 2016-03-01 2016-04-13 Apitope Int Nv Peptides
ES2996275T3 (en) * 2017-01-04 2025-02-12 Worg Pharmaceuticals Zhejiang Co Ltd Therapeutic method using dose escalation protocol for tolerogenic peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
US20210093695A1 (en) * 2017-08-14 2021-04-01 Apitope Technology (Bristol) Limited Method
JP2024518277A (ja) 2021-04-16 2024-05-01 クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド 免疫寛容の維持を追跡する方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016410A2 (en) * 2000-08-21 2002-02-28 Apitope Technology (Bristol) Limited Peptide selection method
WO2003064464A1 (en) * 2002-02-01 2003-08-07 Apitope Technology (Bristol) Limited Tolerogenic peptides from myelin basic protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US20040096456A1 (en) 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
US8623827B2 (en) 2007-10-31 2014-01-07 Apitope Technology (Bristol) Limited Myelin basic protein peptide composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016410A2 (en) * 2000-08-21 2002-02-28 Apitope Technology (Bristol) Limited Peptide selection method
EP1731912A2 (en) * 2000-08-21 2006-12-13 Apitope Technology (Bristol) Limited Peptide selection method
WO2003064464A1 (en) * 2002-02-01 2003-08-07 Apitope Technology (Bristol) Limited Tolerogenic peptides from myelin basic protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANNONYMOUS.ATX-MS1467 vaccine declared for U.K phase I study in MS.《PROUS SCIENCE INTEGRITY》.2007,全文. *

Also Published As

Publication number Publication date
US8623827B2 (en) 2014-01-07
IL204662A (en) 2013-07-31
PL2211892T3 (pl) 2012-01-31
US9775880B2 (en) 2017-10-03
CN101848725A (zh) 2010-09-29
WO2009056833A2 (en) 2009-05-07
ATE518546T1 (de) 2011-08-15
ECSP10010211A (es) 2010-08-31
WO2009056833A3 (en) 2009-11-26
CY1112620T1 (el) 2016-02-10
HK1142803A1 (en) 2010-12-17
EA201070541A1 (ru) 2010-12-30
NZ583924A (en) 2012-06-29
MX2010004698A (es) 2010-05-13
EA017999B1 (ru) 2013-04-30
CA2703170C (en) 2016-10-11
HRP20110724T1 (hr) 2011-12-31
US20140161832A1 (en) 2014-06-12
EP2211892B1 (en) 2011-08-03
SI2211892T1 (sl) 2011-12-30
US9381234B2 (en) 2016-07-05
US20100286054A1 (en) 2010-11-11
PT2211892E (pt) 2011-10-18
BRPI0818302A2 (enExample) 2018-08-21
JP2011500776A (ja) 2011-01-06
MY158800A (en) 2016-11-15
KR101570383B1 (ko) 2015-11-19
ZA201001748B (en) 2011-06-29
DK2211892T3 (da) 2011-10-31
AU2008320657A1 (en) 2009-05-07
BRPI0818302B1 (pt) 2022-04-12
EP2211892A2 (en) 2010-08-04
IL204662A0 (en) 2010-11-30
KR20100036391A (ko) 2010-04-07
US20160263188A1 (en) 2016-09-15
JP5361895B2 (ja) 2013-12-04
CA2703170A1 (en) 2009-05-07
AU2008320657B2 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
CN101848725B (zh) 组合物
US8343500B2 (en) Peptide composition
RU2676149C2 (ru) Пептиды
EP0522091B1 (en) Use of a mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
EP0650498B1 (en) Suppression of t-cell proliferation using peptide fragments of myelin basic protein
AU2025201115A1 (en) Method
AU2018206358A1 (en) S-Arrestin peptides and therapeutic uses thereof
Holmes et al. Multiple sclerosis: MHC associations and therapeutic implications
ES2370957T3 (es) Composiciones que comprenden péptidos de la proteína básica de la mielina y sus utilizaciones médicas.
HK1142803B (en) Compositions comprising myelin basic protein peptides and medical uses thereof
HK1219058B (en) Peptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20230525

Address after: Room 215, Building 2, No. 198, Peninsula Middle Road, Dipu Street, Anji County, Huzhou City, Zhejiang Province

Patentee after: Baimingxinkang Biotechnology (Zhejiang) Co.,Ltd.

Address before: Bristol

Patentee before: APITOPE TECHNOLOGY (BRISTOL) Ltd.